ERBB2 and duodenal adenocarcinoma: Another study of 83 patients confirmed these findings, reporting increased ERBB2 mutation rate in duodenal adenocarcinomas (15.8%) compared to jejunal and ileal adenocarcinomas (2.2%) [30].